| Chitra Ramakrishnan, MD | |
|
959 E Walnut St, Suite 120, Pasadena, CA 91106-1451 | |
| (626) 795-5118 | |
| (626) 795-2716 |
| Full Name | Chitra Ramakrishnan |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 959 E Walnut St, Pasadena, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134194186 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | A75747 (California) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | A75747 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Huntington Memorial Hospital | Pasadena, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthcare Partners Affiliates Medical Group | 7315842002 | 658 |
News Archive
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
A large study of US adults, conducted collaboratively by state health departments and the CDC, has shown that over a third of the population are regularly not getting enough sleep. This is the first study to obtain self-reported estimates of sleep duration for all 50 US states and the District of Columbia.
Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.
An estimated 1.2 million people in the United States have an abdominal aortic aneurysm (AAA) - a dangerous bulge or ballooning in their bodies' main artery that typically causes no symptoms until it ruptures, which can be deadly - and most of them don't know it. But for those with a known AAA of a certain size, there's a new medical device for a safe and effective treatment option that doesn't require major surgery, an extended hospital stay and a long recovery period.
› Verified 8 days ago
| Entity Name | Healthcare Partners Affiliates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659312593 PECOS PAC ID: 7315842002 Enrollment ID: O20031204001258 |
News Archive
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
A large study of US adults, conducted collaboratively by state health departments and the CDC, has shown that over a third of the population are regularly not getting enough sleep. This is the first study to obtain self-reported estimates of sleep duration for all 50 US states and the District of Columbia.
Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.
An estimated 1.2 million people in the United States have an abdominal aortic aneurysm (AAA) - a dangerous bulge or ballooning in their bodies' main artery that typically causes no symptoms until it ruptures, which can be deadly - and most of them don't know it. But for those with a known AAA of a certain size, there's a new medical device for a safe and effective treatment option that doesn't require major surgery, an extended hospital stay and a long recovery period.
› Verified 8 days ago
| Entity Name | Foothill Pulmonary & Critical Care Consultants Medical Group Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205862489 PECOS PAC ID: 9234172891 Enrollment ID: O20050603001043 |
News Archive
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
A large study of US adults, conducted collaboratively by state health departments and the CDC, has shown that over a third of the population are regularly not getting enough sleep. This is the first study to obtain self-reported estimates of sleep duration for all 50 US states and the District of Columbia.
Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.
An estimated 1.2 million people in the United States have an abdominal aortic aneurysm (AAA) - a dangerous bulge or ballooning in their bodies' main artery that typically causes no symptoms until it ruptures, which can be deadly - and most of them don't know it. But for those with a known AAA of a certain size, there's a new medical device for a safe and effective treatment option that doesn't require major surgery, an extended hospital stay and a long recovery period.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chitra Ramakrishnan, MD 959 E Walnut St, Suite 120, Pasadena, CA 91106-1451 Ph: (626) 795-5118 | Chitra Ramakrishnan, MD 959 E Walnut St, Suite 120, Pasadena, CA 91106-1451 Ph: (626) 795-5118 |
News Archive
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
A large study of US adults, conducted collaboratively by state health departments and the CDC, has shown that over a third of the population are regularly not getting enough sleep. This is the first study to obtain self-reported estimates of sleep duration for all 50 US states and the District of Columbia.
Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.
An estimated 1.2 million people in the United States have an abdominal aortic aneurysm (AAA) - a dangerous bulge or ballooning in their bodies' main artery that typically causes no symptoms until it ruptures, which can be deadly - and most of them don't know it. But for those with a known AAA of a certain size, there's a new medical device for a safe and effective treatment option that doesn't require major surgery, an extended hospital stay and a long recovery period.
› Verified 8 days ago
Ms. Kimberly Anne Shriner, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 50 Alessandro Pl, Suite 360, Pasadena, CA 91105 Phone: 626-793-6133 Fax: 626-793-6135 | |
Praneet Kalkat, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 960 E Green St Ste 105, Pasadena, CA 91106 Phone: 626-304-0782 Fax: 626-310-0552 | |
Gargi H Upadhyaya, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 1121 Arden Rd, Pasadena, CA 91106 Phone: 626-256-4673 | |
Lu Jiao, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S Fair Oaks Ave, Suite 300, Pasadena, CA 91105 Phone: 626-795-7556 | |
Kristin J Karlyn, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1044 S Fair Oaks Ave Ste 101, Pasadena, CA 91105 Phone: 626-734-7870 Fax: 626-593-6550 | |
Dr. Glenn David Littenberg, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 630 S Raymond Ave, Suite 240, Pasadena, CA 91105 Phone: 626-449-9920 Fax: 626-578-7366 | |
Dr. Robert E Ladines, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1515 N Fair Oaks Ave, Pasadena, CA 91103 Phone: 626-798-1111 Fax: 626-345-1901 |